Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Pediatric Hematology, Amsterdam, the Netherlands; Sanquin Research and Landsteiner Laboratory, Immunopathology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Pediatric Hematology, Amsterdam, the Netherlands.
Blood Rev. 2021 Jul;48:100794. doi: 10.1016/j.blre.2020.100794. Epub 2021 Jan 5.
Red blood cell (RBC) alloimmunization is a serious complication of blood transfusions, challenging selection of compatible units for future transfusions. Genetic characteristics may be associated with the risk of RBC alloimmunization and may therefore serve to identify high-risk patients. The aim of this systematic review was to summarize the available evidence on genetic risk factors for RBC alloimmunization. Electronic databases were searched up to April 2020 for studies (Search terms included transfusion, alloimmunization and genetic). A total of 2581 alloimmunized cases and 26,558 controls were derived from 24 studies. The alleles that were most frequently studied and that demonstrated significant associations in a meta-analysis with alloimmunization to the Duffy antigen were HLA-DRB104 (Odds Ratio 7.80 (95%CI 4.57-13.33)), HLA-DRB115 (OR 3.76 (95%CI 2.14-6.59)), and HLA-DRB103 (OR 0.12 (95%CI 0.05-0.29)). Furthermore, significant associations with anti-K formation was found for the alleles HLA-DRB110 (OR 2.64 (95%CI 1.41-4.95)), HLADRB111 (OR 2.11, (95%CI 1.34-3.32)), and HLA-DRB1*13 (OR 1.71 (95%CI 1.26-2.33)). Overall, the available evidence was of moderate to low quality, hampering interpretation of reported results. There is an urgent need for high quality evidence on genetic risk factors for RBC alloimmunization.
红细胞(RBC)同种免疫是输血的严重并发症,对未来输血时选择相容单位构成挑战。遗传特征可能与 RBC 同种免疫的风险相关,因此可以用来识别高危患者。本系统综述的目的是总结红细胞同种免疫遗传危险因素的现有证据。电子数据库搜索截至 2020 年 4 月,检索词包括输血、同种免疫和遗传。共有 24 项研究纳入了 2581 例同种免疫病例和 26558 例对照。在荟萃分析中,与 Duffy 抗原同种免疫最常研究的等位基因和显示出显著关联的等位基因为 HLA-DRB104(优势比 7.80(95%CI 4.57-13.33)),HLA-DRB115(OR 3.76(95%CI 2.14-6.59))和 HLA-DRB103(OR 0.12(95%CI 0.05-0.29))。此外,还发现与抗-K 形成相关的等位基因 HLA-DRB110(OR 2.64(95%CI 1.41-4.95)),HLADRB111(OR 2.11,(95%CI 1.34-3.32))和 HLA-DRB1*13(OR 1.71(95%CI 1.26-2.33))。总体而言,现有证据的质量为中等到低,阻碍了对报告结果的解释。迫切需要高质量的红细胞同种免疫遗传危险因素证据。